GGrantIndex
← Leaderboards

Jill E Bargonetti

Hunter College

$4,139,233
Attributed
$4,139,233
Total exposure
5
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $450.6K · FY200525
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,139,233 · 5

By mechanism

R01$1,781,178 · 1
SC1$1,256,880 · 1
S06$854,469 · 2
U54$246,706 · 1

Top collaborators

No co-investigators on record.

Most similar at Hunter College

Same institution · by research overlap

Others in their field

Top investigators on “Dna Damage

Research focus

Dna DamageCell LineTp53 GeneSignal TransductionProteinsTumorMutantMalignant NeoplasmsComplexMutationPathway InteractionsMitomycinsCellsCell Culture TechniquesMediatingGenesPublishingCancer CellApoptosisP53 Gene /ProteinCell CycleCell DeathCell KillingInnovation

Grant awards (23)

Pilot Research Project: Evaluating Breast Cancer Patient Populations for Therapeutic Targeting of Aberrant p53, MDM2, MDMX, and PARP signaling$68,985
U54 · FY2025 · CA · contact PI
The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast Cancer$328,101
R01 · FY2024 · CA · contact PI
Pilot Research Project: Evaluating Black and African American Breast Cancer Populations for Therapeutic Targeting of Aberrant p53, MDM2, MDMX, and PARP signaling$65,537
U54 · FY2024 · CA · contact PI
The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast Cancer$338,463
R01 · FY2023 · CA · contact PI
Pilot Research Project: Evaluating Black and African American Breast Cancer Populations for Therapeutic Targeting of Aberrant p53, MDM2, MDMX, and PARP signaling$112,184
U54 · FY2023 · CA · contact PI
The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast Cancer$357,342
R01 · FY2022 · CA · contact PI
The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast Cancer$368,017
R01 · FY2021 · CA · contact PI
The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast Cancer$389,255
R01 · FY2020 · CA · contact PI
p53-Independent Cell Death Signaling by Mitomycin DNA Adducts$294,880
SC1 · FY2011 · CA · contact PI
p53-Independent Cell Death Signaling by Mitomycin DNA Adducts$304,000
SC1 · FY2010 · CA · contact PI
p53-Independent Cell Death Signaling by Mitomycin DNA Adducts$329,000
SC1 · FY2009 · CA · contact PI
p53-Independent Cell Death Signaling by Mitomycin DNA Adducts$329,000
SC1 · FY2008 · CA · contact PI
Mitomycin C (MC) and 10-decarbamoyl MC Signaling to p53 and Family Members$220,035
S06 · FY2007 · GM · contact PI
Mitomycin C (MC) and 10-decarbamoyl MC Signaling to p53 and Family Members$114,957
S06 · FY2006 · GM · contact PI
Mitomycin C (MC) and 10-decarbamoyl MC Signaling to p53 and Family Members$111,667
S06 · FY2005 · GM
Mitomycin C (MC) and 10-decarbamoyl MC Signaling to p53 and Family Members$136,968
S06 · FY2004 · GM
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE$30,384
S06 · FY2002 · GM
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE$30,384
S06 · FY2002 · GM
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE$30,384
S06 · FY2002 · GM
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE$59,461
S06 · FY2001 · GM
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE$30,384
S06 · FY2001 · GM
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE$30,384
S06 · FY2001 · GM
MITOMYCIN SIGNALING TO AND FROM P53 DURING THE CELL CYCLE$59,461
S06 · FY2000 · GM